Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
JBMR Plus|July 14, 2021
Skeletal responses to romosozumab after 12 months of denosumabMichael R McClung, Michael A Bolognese, Jacques P Brown, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 6, 2020
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumabM R McClung, M A Bolognese, J P Brown, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massHenry G Bone, Michael A Bolognese, Chui Kin Yuen, et al.
Clinical Therapeutics|March 6, 2012
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled studyDale A Schoeller, Achilles Alon, Demetrios Manekas, et al.
The Journal of Clinical Investigation|April 1, 1982
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteersJ A Tobert, G D Bell, J Birtwell, et al.
The Journal of Clinical Endocrinology and Metabolism|August 1, 1996
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young menG Copinschi, A Van Onderbergen, M L'Hermite-Balériaux, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 11, 2012
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialM R McClung, E M Lewiecki, M L Geller, et al.
Gastroenterology|November 8, 2006
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomasJohn A Baron, Robert S Sandler, Robert S Bresalier, et al.
Mayo Clinic Proceedings|March 13, 2002
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trialsHugh Taggart, Michael A Bolognese, Robert Lindsay, et al.
Neuroendocrinology|February 12, 1998
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in manG Copinschi, R Leproult, A Van Onderbergen, et al.
Pageof 17